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The prenyl-binding protein PDEd is crucial for the plasma membrane localization of
prenylated Ras. Recently, we have reported that the small-molecule Deltarasin binds to the
prenyl-binding pocket of PDEd, and impairs Ras enrichment at the plasma membrane, thereby
affecting the proliferation of KRas-dependent human pancreatic ductal adenocarcinoma
cell lines. Here, using structure-based compound design, we have now identiﬁed
pyrazolopyridazinones as a novel, unrelated chemotype that binds to the prenyl-binding
pocket of PDEd with high afﬁnity, thereby displacing prenylated Ras proteins in cells. Our
results show that the new PDEd inhibitor, named Deltazinone 1, is highly selective, exhibits
less unspeciﬁc cytotoxicity than the previously reported Deltarasin and demonstrates a high
correlation with the phenotypic effect of PDEd knockdown in a set of human pancreatic
cancer cell lines.
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T
he products of the proto oncogene Ras in the GTP-bound
state1 recruit effector proteins to the plasma membrane
(PM) that activate proliferation- and survival-signalling in
cells2,3. Oncogenic mutations of speciﬁc amino acids (AA), most
commonly AA12, 13 and 61, maintain Ras in the constitutively
active, GTP-bound state4, resulting in aberrant signalling. The
most commonly mutated Ras isoform is KRas4B (from here on
called KRas), which occurs in more than 90% of pancreatic,
45% of colorectal and 30% of lung tumours4.
Signal transduction of KRas strongly depends on its
enrichment at the PM5. The localization motifs of KRas, a
farnesylated cysteine and a polybasic stretch in the C-terminal
hypervariable region6, are not sufﬁcient to counter entropic
equilibration to the extensive endomembrane surfaces7. A major
role in counteracting this equilibration to endomembranes is
played by the guanine nucleotide dissociation inhibitor (GDI)-
like solubilization factor PDEd8–11. It sequesters KRas from the
cytosol by binding the farnesyl moiety, preventing that KRas
binds to endomembranes and thereby enhancing its diffusion
throughout the cell. KRas is then released in perinuclear
membranes by the local activity of the release factor Arl2 (ref.
12), from where it is trapped by electrostatic interaction on the
recycling endosome and shuttled back to the PM via vesicular
transport7. Any interference with this cycle—such as competitive
inhibition of PDEd—will cause an entropy-driven relocalization
of KRas to the extensive endomembrane surfaces7,8,13. Besides
KRas, the PDEd/Arl2 system is also crucial for maintaining
membrane localization of other proteins of the Ras family, such as
palmitoylated H- and N-Ras, as well as localization of the solely
farnesylated Rheb on perinuclear membranes5. Delocalization of
these Ras family molecules by interference with the PDEd/Arl2
system is also expected to have a negative effect on cell growth
and proliferation.
There have been many attempts to either target oncogenic
Ras directly, its posttranslational modiﬁcations or downstream
effectors with limited success4,14–16. Reducing PM localization of
Ras through PDEd inhibition raises alternative opportunities to
impede oncogenic Ras signalling. The small-molecule Deltarasin
affects the PM localization of KRas by competitively binding
to the prenyl-binding pocket of PDEd, relocating KRas to
endomembranes. This KRas relocalization resulted in reduced
proliferation of oncogenic KRas-dependent human pancreatic
ductal adenocarcinoma cell lines (hPDACs)13.
However, subsequent detailed analysis of the dose–response
curves characteristic for Deltarasin revealed that this PDEd ligand
displays a ‘switch-like’ inhibition of proliferation; that is, the
corresponding dose–response curve is very steep in the 3–8 mM
range with a Hill coefﬁcient of  5.3 to  10.8 (Supplementary
Fig. 1). Such behaviour could arise from non-linear effects of
Ras plasma membrane localization on signalling or could
be indicative of general cytotoxicity by Deltarasin at high
concentration and/or of interaction with additional target
proteins in cells causing undesired side effects. Indeed, analysis
of Deltarasin binding to additional proteins revealed that the
compound also binds to different G-protein-coupled receptors,
ion channels and transporters (Supplementary Table 1). Given
this undesirable property of Deltarasin at concentrations45 mM,
validation of PDEd as potential target for small-molecule
interference with Ras localization and thereby also signalling
activity, called for the development of a novel chemotype for
inhibition of the Ras–PDEd interaction, which would not display
a comparable general cytotoxicity.
Herein, we describe the discovery of pyrazolopyridazinones as
a novel PDEd inhibitor chemotype that targets the prenyl-binding
pocket of PDEd with low nanomolar afﬁnity. Structure-based
ligand development led to the identiﬁcation of the PDEd ligand
Deltazinone 1, which binds to PDEd with high selectivity, shows
anti-proliferative activity over a wide concentration range and is
not generally cytotoxic. We demonstrate that inhibition of the
PDEd/Ras interaction by Deltazinone 1 is closely correlated to the
phenotypic consequences of RNAi-mediated PDEd knockdown
in a panel of human pancreatic cancer cell lines.
Results
Synthesis of PDEd inhibitors based on a different scaffold.
To identify alternative chemotypes for the inhibition of the
PDEd/Ras interaction with potency similar to Deltarasin (Fig. 1a,
KD¼ 38±16 nM), an in-house library of B150,000 compounds,
assembled considering structural diversity of the underlying
scaffolds, drug-likeness, coverage of different established drug
target classes and inspiration by natural products, was subjected
to high-throughput screening by means of the previously
developed AlphaScreen Technology13. The screen revealed
pyrazolopyridazinone 2a (KD¼ 5±2 nM) as ligand of the
prenyl-binding pocket of PDEd (Fig. 1b).
Structure-based development of the pyrazolopyridazinone hit
class was enabled by a crystal structure of inhibitor 2a in complex
with PDEd at a resolution of 2.6 Å (Fig. 1d) which revealed that,
like inhibitors of the Deltarasin-type, heterocycle 2a employs
H-bonds to Tyr 149 and Arg 61 for binding to PDEd13. Initial
screening and molecular modelling investigations (Schro¨dinger,
Maestro suite) revealed that a C-3 linker between the two
hydrogen-bonding groups is important and that shortening of the
linker would abrogate H-bond formation between the amide
carbonyl and Tyr 149 (Fig. 1f). Therefore, a C-3 linker was kept
for further inhibitor development.
Since anilides display low metabolic stability, we searched
for an alternative to the anilide embodied in hit compound 2a.
Initial investigations and modelling revealed benzyl- and
homobenzylamides as potential inhibitors, since they could adopt
a conformation in which an H-bond with Tyr 149 is formed and
the empty space in the PDEd pocket is ﬁlled. Therefore, a series
of compounds with these constraints was synthesized and
investigated (Table 1). As shown in Table 1, benzyl amide 2c
also binds to PDEd with nanomolar afﬁnity. Reduction of the ring
size (entry 2) or incorporation of a substituent on the phenyl ring
was not favourable (entries 4 and 5). In addition, modelling
indicated that a small substituent might be attached to the
N-phenyl moiety, pointing deep into the farnesyl-binding site.
Indeed, incorporation of a p-methyl substituent into the pyrazole
N-phenyl ring resulted in low nanomolar afﬁnity (entries 2, 3, 6
versus 7, 8, 9). Besides benzyl amides, homobenzyl amides are
also very potent inhibitors displaying low nanomolar afﬁnities
(entries 6, 9–11).
Compound 2k (Fig. 1c) was selected because it embodies one
metabolically unstable benzylic position less than compound 2j.
As compared with compound 2i, we assumed that the presence of
an additional methyl group at the benzylic position in 2k would
further stabilize the compound with respect to metabolic
degradation. Based on the fact that pyrazolopyridazinone 2a
binds to PDEd like the Deltarasin-type inhibitors (Fig. 1d),
molecular modelling experiments indicated that 2k will form the
same hydrogen bonds as Deltarasin and may additionally form a
hydrogen bond with glutamine 78 (Fig. 1e). Compound 2k was,
therefore, subjected to a panel of biochemical and pharmaco-
logical screens to determine its selectivity proﬁle and possible
interactions with other pharmacologically relevant proteins.
This compound proved to be more selective as compared with
Deltarasin in the selected panel of targets (Supplementary Fig. 2
and Supplementary Table 1) and was chosen for further
investigations in cells. We named this compound Deltazinone 1.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11360
2 NATURE COMMUNICATIONS | 7:11360 | DOI: 10.1038/ncomms11360 | www.nature.com/naturecommunications
Deltazinone 1 inhibits the PDEd–Ras interaction. To compare
the inhibition of PDEd by Deltazinone 1 to Deltarasin, the
interaction between farnesylated Ras proteins and PDEd was
measured in live cells by ﬂuorescence lifetime imaging micro-
scopy of Fo¨rster resonance energy transfer (FLIM-FRET)13. For
this, Madin–Darby canine kidney (MDCK) cells were transiently
transfected with Rheb N-terminally fused to a yellow ﬂuorescent
protein (mCitrine-Rheb), and PDEd fused to a red ﬂuorescent
protein variant (mCherry-PDEd). Rheb is a farnesylated Ras
protein that lacks the polybasic stretch in the hypervariable
region, resulting in a low membrane afﬁnity and an enhanced
fraction that can interact with PDEd in the cytoplasm.
This facilitates the detection of small-molecule effects on
the interaction between farnesylated proteins and PDEd by
FLIM-FRET. The ﬂuorescence patterns of mCitrine-Rheb and
mCherry-PDEd in the absence of the inhibitor showed a
homogeneous distribution, demonstrating that mCitrine-Rheb is
solubilized by mCherry-PDEd (Fig. 2a,b). This was reﬂected
in the high molar fraction (a) of interacting Rheb-PDEd
as measured by FLIM-FRET. Increasing concentrations of
Deltazinone 1 or Deltarasin resulted in a reduced interaction
of mCitrine-Rheb with mCherry-PDEd that was paralleled
by a relocalization of mCitrine-Rheb to endomembranes.
Dose-dependent measurements yielded an ‘in-cell’ KD of
58±17 nM for Deltazinone 1 and 66±5 nM for Deltarasin.
To measure whether both inhibitors also affect the interaction
of KRas with PDEd, MDCK cells were transiently transfected with
mCitrine-KRas and mCherry-PDEd. The cytosolic fraction of
KRas is much lower than the one of Rheb due to its higher PM
afﬁnity caused by its polybasic stretch5. This leads to a smaller
fraction of mCitrine-KRas interacting with mCherry-PDEd at
steady state in the cytoplasm, making the interaction difﬁcult to
detect with FLIM-FRET. To increase the fraction of KRas that
interacts with PDEd, the Protein Kinase C (PKC) activator
Bryostatin, which induces serine (S181) phosphorylation on
KRas17, was applied, resulting in a reduced electrostatic
interaction with the PM and increased cytosolic pool of
mCitrine-KRas. Subsequent addition of 5mM Deltazinone 1
(Fig. 2c) or Deltarasin (Fig. 2d) abolished the interaction between
mCitrine-KRas and mCherry-PDEd and resulted in relocalization
of KRas to endomembranes.
Deltazinone 1 impairs growth of KRas-dependent hPDAC cells.
To compare the effects of PDEd knockdown with small-molecule
PDEd inhibition on proliferation, impedance-based real-time cell
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Figure 1 | Identiﬁcation of a novel KRas-PDEd inhibitor chemotype. Structure and binding afﬁnities (KD, determined by competitive ﬂuorescence
polarization assay of three independent experiments, see Supplementary Information) of (a) Deltarasin 1a and allyl analogue 1b (b) pyrazolopyridazinone
derivative 2a and (c) Deltazinone 1 2k. (d) Superimposition (middle) of the crystal structures of compounds 1b (PDB code: 4JVB) and 2a (PDB code: 5E80)
in the PDEd-binding pocket. The magniﬁcation on the left shows the structure of 1b (1.75Å) and of 2a (2.60Å) on the right side of the superimposition.
Tyr149 (Y149) and Arg61 (R61) are shown as sticks to highlight the hydrogen bond interactions. (e) Predicted binding mode of Deltazinone 1, 2k
(best docking pose; Schro¨dinger, Maestro suite). Besides Y149 and R61, Gln78 (Q78) is also shown as stick to highlight the probable third H-bond
interaction. (f) Best docking poses for a series of N-benzyl pyrazolopyridazinone derivatives containing linker chains with one, two, three (compound 2a)
and four methylene units. Distances for hypothetical hydrogen bonding with Tyr149 and Arg61 are shown.
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analyser (RTCA) measurements were performed in a panel of
pancreatic cancer cell lines (Table 2, Fig. 3). For this, all
pancreatic cancer cell lines were transduced with the previously
reported doxycycline-induced short hairpin RNA (shRNA)
construct against PDEd13.
The doxycycline-induced PDEd knockdown in the oncogenic
KRas-dependent human carcinoma cell lines Panc-Tu-I, Capan-1
and MIA PaCa-2 (refs 18,19) resulted in a strongly reduced
proliferation after 70–110 h (Fig. 3a), whereas treatment of
the parental cell lines with doxycycline did not alter their
proliferation (Supplementary Fig. 3).
This correlated with the growth inhibitory effects of
both small-molecule inhibitors in these cell lines (Fig. 3b,c).
Deltazinone 1 inhibited cell growth in a dose-dependent manner
already observable at sub-mM concentrations. At doses higher
than 3 mM decreasing cell indices indicated cell deathB30 h after
Deltazinone 1 administration in Panc-Tu-I cells and after B40 h
in MIA PaCa-2 (Fig. 3b). In the Capan-1 cell line, Deltazinone 1
doses up to 24 mM led to strong growth inhibition but not cell
death. This differential behaviour of the three KRas-dependent
cell lines to PDEd inhibition was reﬂected in the growth of these
cells after doxycycline-induced PDEd knockdown (Fig. 3a). In
contrast to treatment with Deltazinone 1, a steep dose-dependent
growth inhibitory effect and cell death was observed for
Deltarasin in a concentration range from 3 to 5 mM in Panc-
Tu-I, Capan-1 and MIA PaCa-2 cell lines (Fig. 3c,d)13. At 5 mM
Deltarasin, detectable cell death in Panc-Tu-I occurredB9 h post
treatment. The onset of Panc-Tu-I cell death after Deltazinone 1
treatment happened much later (B13h for 24mM Deltazinone 1),
while the onset was dependent on the dose of the drug (Fig. 3e).
This indicates that Deltazinone 1 is less potent than Deltarasin in
inhibiting the PDEd/Arl2 system that restores KRas plasma
membrane localization (see Discussion).
PANC-1 cells that harbour oncogenic KRas but are indepen-
dent of this oncogene18, as well as the KRas wild-type-expressing
BxPC-3 cancer cell line exhibited minor growth inhibitory effects
on doxycycline-induced shRNA knockdown of PDEd. Similarly,
Deltazinone 1 doses up to 24 mM had little or no growth
Table 1 | KD values for pyrazolopyridazinones with different amide structures and N-phenyl substituents as determined by means
of ﬂuorescence polarization assay.
Entry 2 R1 R2 KD [nM]
1 2a H 5 ± 2
2 2b H 136 ± 55 
3 2c H 42 ± 15 
4 2d H 81 ± 21 
5 2e H 96 ± 14 
6 2f H 29 ± 7 
7 2g CH3 50 ± 16 
8 2h CH3 17 ± 9 
9 2i CH3 6 ± 2
10 2j CH3 5 ± 3
11 2k CH3 8 ± 4*
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*(S)-2k KD¼ 5±3 nM; (R)-2k KD¼ 12±4 nM.
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inhibitory effect on these cell lines (Fig. 3a,b). In contrast,
Deltarasin concentrations above 9 mM resulted in an abrupt
change in the RTCA proﬁles indicating rapid cell death of the
KRas-independent cancer cell lines (Fig. 3c). These results
point at unspeciﬁc cytotoxicity of Deltarasin at concentrations
above 9mM, which was not observed for Deltazinone 1 for
concentrations up to 24 mM. The RTCA measurements were
corroborated by long-term time-lapse microscopy that showed
cell death for oncogenic KRas-dependent Panc-Tu-I cells treated
with 5 mM Deltarasin or 10 mM Deltazinone 1, but not for
oncogenic KRas-independent PANC-1 cells (Supplementary
Movies 1–6).
PDEd inhibition decreases Ras-mediated signalling. MAPK and
mTOR pathways, which regulate proliferation and growth,
are regulated by activity of proteins from the Ras family
(Ras and Rheb, respectively)15,20. To examine whether PDEd
inhibition by Deltarasin and Deltazinone 1 downregulates the
signal transduction via these pathways, we examined the
phosphorylation of extracellular signal regulated kinase (Erk)
and S6 Ribosomal Protein (S6P) in the oncogenic KRas-
dependent Panc-Tu-1 and KRas-independent PANC-1 cells.
Following treatment with Deltarasin or Deltazinone 1 for 1 h,
phosphorylation levels of Erk and S6P were determined before
a
0 20 40 60 80 160 320 5,000 nM Deltazinone 1
m
Ch
er
ry
-
PD
E 
δ
m
Ci
tri
ne
-
R
he
b
α
b
0 20 40 60 80 160 320 5,000 nM Deltarasin
m
Ch
er
ry
-
PD
E 
δ
m
Ci
tri
ne
-
R
he
b
α
c
Pre  Bryostatin Deltazinone 1
m
Ch
er
ry
-
PD
E 
δ
m
Ci
tri
ne
-
KR
as
α
d
m
Ch
er
ry
-
PD
E 
δ
m
Ci
tri
ne
-
KR
as
α
Bryostatin DeltarasinPre
0.5
0
0.3
–0.2
–0.15
0.3
0.3
KD 57.8 ± 16.9 nM
r2 = 0.96
KD 65.6 ± 5.3 nM
r2 = 0.99
Deltazinone 1 (nM)
0 100 200 300 400
0.10
0.15
0.20
0.25
0.00
0.05
α
 
(no
rm
a
liz
e
d 
to
 0
.2
)
α
 
(no
rm
a
liz
e
d 
to
 0
.2
)
0 100 200 300 400
0.10
0.15
0.20
0.25
0.00
0.05
–0.05
–0.15
Deltarasin (nM)
Figure 2 | In-cell measurement of the effect of Deltarasin or Deltazinone 1 on the interaction between Ras proteins and PDEd. Dose–response
measured by the interacting fraction (a) of mCitrine-Rheb with mCherry-PDEd for Deltazinone 1 (a) and Deltarasin (b) as determined by FLIM-FRET.
The inhibitor concentration is indicated at the top of each image in nM. Right panels, ﬁt of averaged dose–response±s.e.m. of nine independent
experiments to a binding model (see Methods) yielded an in-cell KD of 58±17 nM for Deltazinone 1 (a) and 66±5 nM for Deltarasin (b). Interacting
fraction (a) of mCitrine-KRas with mCherry-PDEd on 5min treatment with 1mM Bryostatin-1 and subsequent addition of 5mM Deltazinone 1 (c) or 5 mM
Deltarasin after 5min (d). First row: ﬂuorescence intensity distribution of mCitrine-Rheb (a,b) or mCitrine-KRas (c,d); second row: ﬂuorescence intensity
distribution of mCherry-PDEd; third row: molar fraction a (false colour coded) of interacting mCitrine-Rheb with mCherry-PDEd (a,b) or mCitrine-KRas
with mCherry-PDEd (c,d). Scale bars, 10mm.
Table 2 | Overview of pancreatic cancer cell lines used
in this study including KRas mutation and oncogenic
KRas-dependence.
Cancer cell line KRas mutation Oncogenic KRas-dependence
PANC-1 G12D No18,19
BxPC3 wt No19
Capan-1 G12V Yes18,19
Panc-Tu-I/Pa-Tu-8902 G12V Yes18
MIA PaCa-2 G12C Yes19
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Figure 3 | Comparison of the RTCA growth proﬁles of pancreatic cancer cell lines after PDEd knockdown to PDEd inhibition by Deltazinone 1 or
Deltarasin. The ﬁrst column (a) shows the effects of doxycycline-induced PDEd knockdown on cell proliferation. Cell indices were measured in the
presence (red) or absence (black) of doxycycline. Doxycycline was added at the beginning of the measurement. The inset in each proﬁle displays
the respective PDEd protein levels determined by western blot in absence and presence of doxycycline after 72 h. The second (b) and third column
(c) show dose-dependent effects of Deltazinone 1 and Deltarasin on cell proliferation, respectively. The small-molecule PDEd inhibitors were added at the
indicated time points (arrow) and concentrations. The cell indices were normalized to the time of administration. Cell indices±s.d. were measured in
duplicates (Capan-1, MIA PaCa-2 and BxPC-3) or triplicates (Panc-Tu-I and PANC-1). (d) Deltazinone 1 or Deltarasin dose versus growth-rate±s.d. as
determined by the integrated area below the curve in the ﬁrst 60 h after drug administration, normalized to the DMSO control. (e) Time interval between
PDEd inhibitor administration and observed cell death in Panc-Tu-I cells. The mean intervals±s.d. are depicted for each drug.
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and after 5min EGF stimulation by quantitative western blot
analysis (Fig. 4). As previously reported13, 5 mM Deltarasin
reduced EGF-induced Erk phosphorylation in the KRas-
dependent Panc-Tu-I cells, but not in PANC-1 cells (Fig. 4a,b),
while the EGF-induced S6P phosphorylation was reduced in both
lines (Fig. 4a,b). In contrast, 20mM Deltazinone 1 administered
for 1 h did not signiﬁcantly affect Erk response to EGF in
both cell lines, but reduced S6P phosphorylation in the
KRas-dependent Panc-Tu-I cells (Fig. 4c). However, on longer
incubation times (43 h) with Deltazinone 1, EGF-induced
Erk phosphorylation was reduced in Panc-Tu-I and S6P
phosphorylation further decreased in a gradual manner, while
PANC-1 cells, remained unaffected (Fig. 4c,d).
Discussion
Deltarasin was the ﬁrst small molecule effectively targeting the
spatial organization of Ras by competing for the farnesyl-binding
pocket of PDEd and thereby resulting in a reduced proliferation
of oncogenic KRas-dependent pancreatic ductal adenocarcinoma
cells13. Herein, we compared the newly developed PDEd inhibitor
Deltazinone 1 based on the pyrazolopyridazinone scaffold to the
benzimidazole-based Deltarasin and the genetic knockdown of
PDEd. Based on a crystal structure of pyrazolopyridazinone 2a
and molecular modelling, Deltazinone 1 has a similar
PDEd-binding mode as previously described for Deltarasin13.
The oncogenic KRas-dependent cell lines, Panc-Tu-I, Capan-1
and MIA PaCa-2 (refs 18,19) exhibited reduced proliferation
and even cell death after PDEd knockdown and inhibitor
treatments. We observed a high correlation between the effects
of shRNA-mediated down-modulation and small-molecule
inhibition of PDEd on the proliferation pattern of the
pancreatic cancer cell lines. However, Deltarasin exhibited
cytotoxic effects at concentrations above 9mM in all tested cell
lines, causing a ‘switch-like’ proliferation to cell death response.
This is likely due to unspeciﬁc binding of Deltarasin to other
proteins (Supplementary Fig. 2 and Supplementary Table 1),
since this general cytotoxicity was not observed after Deltazinone
1 administration or PDEd knockdown by shRNA. In contrast,
Deltazinone 1 showed a more graded, dose-dependent inhibitory
response on proliferation in oncogenic KRas-dependent cell
lines and no general cytotoxicity could be observed at the
concentrations tested.
Both Deltarasin and Deltazinone 1 exhibited an ‘in-cell’
measured KD of B60 nM for PDEd, whereas mM concentrations
of the inhibitors were required to affect the proliferation of
KRas-dependent pancreatic cancer cells. Part of the explanation is
the strong electrostatic interaction of KRas with negatively
charged membranes that results in a very slow entropic leakage
from the PM7. This means that PDEd needs to be completely
inhibited to relocalize KRas to endomembranes, as even a small
pool of uninhibited, free PDEd is sufﬁcient to reinstate PM
localization of KRas5.
The perinuclear localization of the Ras family protein Rheb
depends solely on farnesylation as it lacks a second feature that
will stabilize the interaction with membranes. For Rheb, the
activity of the PDEd-Arl2 ‘pump’ is essential for maintenance of
its localization, as it counters the tendency of this protein to
distribute on all endomembranes within the cell. Due to the
higher off-rate of Rheb from membranes as compared with
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Figure 4 | Effects of Deltarasin and Deltazinone 1 on Erk and S6P phosphorylation in human pancreatic ductal adenocarcinoma cell lines.Western blot
analysis of Erk and S6P phosphorylation in KRas-dependent Panc-Tu-I (a,c) and KRas-independent PANC-1 cells (b,d). (a,b) Serum-starved cells were
treated with vehicle control (DMSO), 5 mM Deltarasin (DR) or 20mM Deltazinone 1 (DZ1) for 1 h. Phosphorylation levels were compared between
unstimulated ( ) and stimulated cells with 200ngml 1 EGF for 5min (5min EGF). Left panels: representative western blots of six independent
experiments for each cell line. From top to bottom row: phosphorylated Erk on Thr202 and Tyr204 (pErk), total level of Erk (tErk), phosphorylated S6P
on Ser235 and Ser236 (pS6P), total level of S6P (tS6P) and loading control (a-Tubulin). Right bar graphs: quantiﬁcation of pErk/tErk±s.e.m. (left) and
pS6P/tS6P±s.e.m. (right) normalized to EGF-stimulated DMSO control (DMSO). (c,d) Long-term treatment (3, 5 and 8 h) of cells with 20mMDeltazinone
1, after which cells were stimulated with 200 ngml 1 EGF for 5min. Quantiﬁcation of pErk/tErk±s.e.m. (left) and pS6P/tS6P±s.e.m. (right) normalized to
EGF-stimulated DMSO control (DMSO). ( ) Represent phosphorylation levels in unstimulated, vehicle control-treated cells. Values were obtained by
averaging three (Panc-Tu-I) and four (PANC-1) independent experiments. P values were determined by applying Student’s unpaired t-test. P values40.4
are labelled as not signiﬁcant (NS).
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KRas, even incomplete PDEd inhibition will almost completely
relocalize it to the extensive endomembrane surface across the
whole cell5, leading to attenuation of mTOR activity, which is
involved in regulation of cellular growth21. It is thus likely that at
lower doses of the inhibitors, Rheb activity is impaired, whereas at
saturating doses the activity of oncogenic KRas is affected.
This was reﬂected in Erk and S6P phosphorylation levels, as
readouts of the Ras-regulated MAPK pathway and the Rheb-
regulated mTOR pathway, respectively. The effects of both
inhibitors were prominent in suppressing S6P phosphorylation in
KRas-dependent cell lines, even after short incubation times (1 h).
However, signiﬁcant effects on Erk phosphorylation could only be
observed after longer incubation time of Deltazinone 1.
Deltarasin was more efﬁcient in downregulating Erk
phosphorylation in the KRas-dependent cell line, Panc-Tu-I,
indicating a tighter interaction with PDEd as compared with
Deltazinone 1. We, however, measured similar afﬁnities of both
compounds for PDEd (B60 nM), which points to a more efﬁcient
displacement of Deltazinone 1 from PDEd by Arl2 activity. This
could lead to more available free PDEd at steady state that can
reinstate KRas PM localization. This could explain why higher
doses of Deltazinone 1 than Deltarasin are needed to affect
oncogenic KRas signalling to counter the allosteric displacement
activity of Arl2.
The herein presented new PDEd inhibitor chemotype caused
speciﬁc cell death in KRas-dependent pancreatic cancer cell lines
without exhibiting general cytotoxic effects for concentrations up
to 24 mM. Deltazinone 1 represents a more speciﬁc second
chemotype of PDEd inhibitors and thereby resembles a non-
cytotoxic compound for future medicinal chemistry studies.
However, we note that pharmacological characterization of
Deltazinone 1 revealed that this compound is rapidly metabolized
in mice (see the Supplementary Fig. 4 and Supplementary
Tables 2 and 3) making it non-suitable for in vivo experiments.
Our results show that a combination of biochemical screening
and structure-guided design enables the development of a novel
inhibitor class for PDEd with comparable potency but higher
selectivity than the previously developed Deltarasin.
Methods
AlphaScreen. Screening based on Alpha technology was conducted in white,
non-binding 1,536-well plates (Corning) in a ﬁnal volume of 6 ml (ref. 13).
For the screen, a mixture of His6-PDEd, and biotinylated KRas-peptide (ﬁnal
concentrations 100 nM and 250 nM in HEPES 20mM, 100mM NaCl, 0.005%
Chaps, pH 7.5) were added to the 1,536-well plates using a Multidrop Combi
(Thermo Fisher Scientiﬁc) device. Compound solutions were directly added from
10mM dimethylsulphoxide (DMSO) stock solutions to a ﬁnal concentration of
10mM using the acoustic dispenser Echo520 (Labcyte Inc.) and the resulting
mixture was incubated for 30min (for dose–response curves, compounds were
tested at concentrations between 5 nM and 10 mM). Premixed Nickel Chelate
Acceptor Beads and Streptavidin Donor Beads were added to a ﬁnal concentration
of 10 mgml 1 using a Multidrop Combi (Thermo Fisher Scientiﬁc) device.
The resulting mixture was incubated at 4 C overnight. Plates were read on a
Paradigm reader (Molecular Devices, Alphascreen 1536 HTS detection cartridge,
temperature 29–33 C).
Displacement titrations for the determination of KD values. Binding to PDEd
was validated and quantiﬁed by means of a displacement assay employing a
ﬂuorescent-tagged analogue of the HMG-CoA reductase inhibitor Atorvastatin
(Lipitor), which has previously been shown to also bind to PDEd22. The Kd values
were determined by the ﬂuorescence polarization competition-binding assay,
which we developed before.
Crystallography. Inhibitor 2a was co-crystallized with PDEd by mixing a solution
of 500 mM small molecule with an equimolar solution of PDEd resulting in 1%
DMSO as a ﬁnal concentration. Crystals were obtained from a Qiagen PEGs suite
(0.2M calcium acetate, 20% (w/v) PEG 3350). For ﬂash freezing, the crystals in
liquid nitrogen, we used cryoprotectant solution containing the mother liquor
components in addition to glycerol. X-rays data were collected at the X10SA
beamline of the Suisse Light Source, Villigen. XDS programme was used for
processing the data. For solving the structures, molecular replacement was applied
using the programme MolRep from the CCP4 software and PDEd without bound
farnesyl group, from the complex PDEd-farnesylated Rheb complex (PDB 3T5G)
as a search model. Further reﬁnement of the model was performed using a
combination of manual reﬁnement (COOT programme) and the maximum
likelihood restrained reﬁnement (REFMAC5 programme). Final validation of the
model using Ramachandran plot statistics showed none of the residues to be
outliers (Supplementary Table 4).
Molecular modelling. Molecular modelling experiments were carried out with the
Maestro 9.1 suite (Schro¨dinger). Both ligand and receptor ﬂexibility were taken
into account by using receptor docking (Glide) in combination with the protein
structure prediction embedded in the programme Prime. Protein Preparation
Wizard (Schro¨dinger Maestro suite) was used to prepare the PDEd co-crystal for
the calculations. Previously obtained X-ray structures were used to deﬁne the active
site. Water molecules were removed from the protein crystal structure, hydrogen
atoms were added and resulting structure was reﬁned by OPLS2005 force ﬁeld.
The minimization was ended when the RMSD reached 0.18 Å. Receptor Grid
Preparation (Glide) was used to generate the protein grid that was subsequently
utilized in docking experiments. The van der Waals radius scaling factor was set to
0.5 with a partial charge cutoff of 0.25. Arg61 was selected as a possible site for
hydrogen bonding. In addition, docking runs were carried out using an additional
hydrogen bond constraint with Tyr149. Ligand preparation for docking was carried
out with LigPrep in Maestro 9.1 and the OPLS_2005 force ﬁeld. Epika was used to
generate possible states at target pH 7.0±4.0. Ligand-docking options in Glide
were used for the ﬁrst round of docking experiments. Under Setting, XP (extra
precision), Dock ﬂexibly, sample nitrogen inversions, sample ring conformation
and Epik state penalties to docking score were selected, amide bonds were
penalized for nonplanar conformation. Under the Ligands section, the Van der
Waals radius scaling factor was set to 0.5 and the docking was set to match at least
one out of two constraints. Several high-score binding poses were generated and
co-crystallized compounds were re-docked and analysed in terms of overlay with
the X-ray structure.
Cell lines and culture conditions. The identity of all cancer cell lines (a kind
gift from Stephan Hahn, Bochum) were tested by STR-DNA typing. Regular tests
for the presence of mycoplasma were negative. Cells were cultured in DMEM
supplemented with 10% fetal calf serum, 1% non-essential amino acids
(PAN-Biotech), 1% L-glutamine (PAN-Biotech). Cells were maintained in a
humidiﬁed incubator with 5% CO2 at 37 C. For viral transduction, the packaging
cell line HEK293T was seeded in 6 cm dishes and transfected next day with the
vector pLKO-PDE6D-572 (ref. 13) using calcium phosphate precipitation. The
following day, the supernatant was collected and used for viral transduction of the
human pancreatic ductal adenocarcinoma cell lines. Selection with puromycine was
done for all cell lines at a concentration between 0.4 and 1.0 mgml 1 starting 1 day
after transduction. Induction of the shRNA PDE6D-572 (ref. 13) expression was
done with 200 ngml 1 doxycycline. For live-cell microscopy, cells were cultured in
four-well Lab-Tek chambers slides (Thermo Scientiﬁc/NUNC). Transfections were
carried out with Effectene (Qiagen) or Lipofectamine 2000 (Invitrogen).
Fluorescence lifetime imaging microscopy. Fluorescence lifetime images were
acquired using a confocal laser-scanning microscope (FV1000, Olympus) equipped
with a time-correlated single-photon counting module (LSM Upgrade Kit,
Picoquant). For detection of the donor (mCitrine), the sample was excited using a
470-nm diode laser (LDH 470, Picoquant) at a 36-MHz repetition frequency.
Fluorescence signal was collected through an oil immersion objective ( 60/1.35
UPlanSApo, Olympus) and spectrally ﬁltered using a narrow-band emission ﬁlter
(HQ 525/15, Chroma). Photons were detected using a single-photon counting
avalanche photodiode (PDM Series, MPD) and timed using a single-photon
counting module (PicoHarp 300, Picoquant).
FLIM data analysis. Intensity thresholds were applied to segment the cells
from the background ﬂuorescence. Data were analysed via global analysis23
to obtain images of the molar fraction (a) of interacting mCitrine-Rheb with
mCherry-PDEd. Effects on a of Deltazinone 1 and Deltarasin was monitored by
FLIM acquisition through a sequential addition of the compounds, followed by
incubation for 10min. Dose–response relationships were determined by plotting
obtained a per addition, using equation:
a¼A0  A½XX½  þKD
where A0 is a in the absence of the inhibitor, A an asymptotic offset and [X]
concentration of the inhibitor in the medium. The a values before the inhibitor
treatment were normalized to the value of 0.2.
Real time cell analysis. RTCA was performed using 16-well E-plates on the Dual
Plate xCELLigence instrument (Roche Applied Science, Indianapolis, IN). This
system measures a dimensionless parameter called cell index, which evaluates the
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ionic environment at an electrode/solution interface and integrates information on
cell number. Depending on the cell line 5 103–1 104 cells were plated in each
well of the 16-well plates in 200ml of cell culture medium. After seeding, cells were
allowed to settle for 30min at room temperature before being inserted into the
xCELLigence instrument in a humidiﬁed incubator at 37 C with 10% CO2. For
RTCA experiments assaying cells stably expressing the inducible shRNA transgene,
cells were seeded onto the E-plates in medium supplemented with 200 ngml 1
doxycycline. For RTCA experiments, the cells were treated with Deltarasin or
Deltazinone 1 after reaching a steady growth (24 h/48 h). The small-molecule
inhibitors were added at indicated time points and in the indicated concentrations.
The amount of DMSO was kept constant between the individual conditions and
did not exceed 0.24 %. Continuous impedance measurements were then monitored
every 15min for up to 200 h. All assays were performed in duplicates. The cell
index was normalized to 1 at the time point of drug administration. To display the
inhibitor-dose growth-response relationship of Deltarasin and Deltazinone 1, the
area below the curve was integrated for 60 h after administration of the drugs and
normalized to the DMSO control.
Western blots. Cells were lysed with RIPA-buffer (20mM Tris pH 7.5, 150mM
NaCl, 0.5mM Na2 EDTA, 1 % sodium deoxycholate, 0.1% sodium dodecyl sulfate,
1% IGEPAL supplemented with Complete Mini EDTA-free protease inhibitor
(Roche Applied Science) and 1% phosphatase inhibitor cocktail 2 and 3 (P5726 and
P0044, Sigma Aldrich), scraped off after 5min on ice and centrifuged at 14,000g
for 20min at 4 C. SDS–polyacrylamide gel electrophoresis was carried out with
10–25 mg of whole-cell lysate from each sample. The gels were blotted onto
polyvinylidene diﬂuoride membrane (Millipore) and blocked for 1 h at room
temperature. Antibodies used for western blotting were: anti-PDE6D (Santa Cruz:
sc-50260, 1:200), anti-Cyclophilin-B (Abcam: Ab160459, 1:3,000), p44/42 MAPK
(Erk1/2) (3A7) (Cell Signaling: 9107, 1:1,000), Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (D13.14.4E) XP (Cell Signaling: 4370, 1:1,000), S6 Ribosomal
Protein (54D2) (Cell Signaling: 2317, 1:500), Phospho-S6 Ribosomal Protein
(Ser235/236) (2F9) (Cell Signaling: 4856, 1:1,000), a Tubulin (Sigma-Aldrich,
T6074, 1:2,500) and matching secondary infrared antibodies IRDye 680 donkey
anti rabbit IgG, IRDye 800 donkey anti mouse IgG, IRDye 800 donkey anti goat
IgG (LI-COR, 1:10,000). Blots were scanned on a LI-COR Odyssey imaging system.
Western blots were quantiﬁed using ImageJ. The background of the blots
was subtracted by applying the rolling ball subtraction with a radius of 50 pixels.
Afterwards the integrated intensity of the bands was measured. Uncropped blots
are shown in Supplementary Fig. 5.
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